Using specific inhibitors of p38 MAPK, SB203580 and SB202190, effectively decreased the p38 kinase activity in MX2‐resistant leukemia cells (K562/MX2, BALL/MX2), but SB202474 (negative control) did not decrease the activity (Fig. 2A and B). This evidence concerns the gene MX2 and leukemia.